These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 36994372)
21. On offer to Ontario consumers three years after legalization: A profile of cannabis products, cannabinoid content, plant type, and prices. Tassone F; Di Ciano P; Liu Y; Rueda S Front Psychiatry; 2023; 14():1111330. PubMed ID: 36873222 [TBL] [Abstract][Full Text] [Related]
22. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use. Pichini S; Mannocchi G; Berretta P; Zaami S; Pirani F; Pacifici R; Busardò FP Ther Drug Monit; 2020 Feb; 42(1):151-156. PubMed ID: 31389860 [TBL] [Abstract][Full Text] [Related]
23. A daily diary investigation of cannabis use and its diet and exercise correlates. Gibson LP; Skrzynski CJ; Giordano GR; Bryan AD Front Psychol; 2023; 14():1217144. PubMed ID: 37599724 [TBL] [Abstract][Full Text] [Related]
24. Old Dog, New Tricks: A Review of Identifying and Addressing Youth Cannabis Vaping in the Pediatric Clinical Setting. Sharma P; Mathews DB; Nguyen QA; Rossmann GL; A Patten C; Hammond CJ Clin Med Insights Pediatr; 2023; 17():11795565231162297. PubMed ID: 36993933 [TBL] [Abstract][Full Text] [Related]
25. Prevalence and correlates of medical cannabis patients' use of cannabis for recreational purposes. Morean ME; Lederman IR Addict Behav; 2019 Jun; 93():233-239. PubMed ID: 30772776 [TBL] [Abstract][Full Text] [Related]
26. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890 [TBL] [Abstract][Full Text] [Related]
27. Price and product variation in Washington's recreational cannabis market. Davenport S Int J Drug Policy; 2021 May; 91():102547. PubMed ID: 31522966 [TBL] [Abstract][Full Text] [Related]
28. Use and Perceptions of Cannabidiol Products in Canada and in the United States. Goodman S; Wadsworth E; Schauer G; Hammond D Cannabis Cannabinoid Res; 2022 Jun; 7(3):355-364. PubMed ID: 33998872 [No Abstract] [Full Text] [Related]
29. Advancing the science on cannabis concentrates and behavioural health. Bidwell LC; Martin-Willett R; Karoly HC Drug Alcohol Rev; 2021 Sep; 40(6):900-913. PubMed ID: 33783029 [TBL] [Abstract][Full Text] [Related]
30. Exploring Consumer Preferences for Cannabis Vaping Products to Support Public Health Policy: A Discrete Choice Experiment. Donnan JR; Johnston K; Coombs M; Najafizada M; Bishop LD Appl Health Econ Health Policy; 2023 Jul; 21(4):651-659. PubMed ID: 37060511 [TBL] [Abstract][Full Text] [Related]
31. Cannabis and mental health: Prevalence of use and modes of cannabis administration by mental health status. Rup J; Freeman TP; Perlman C; Hammond D Addict Behav; 2021 Oct; 121():106991. PubMed ID: 34087766 [TBL] [Abstract][Full Text] [Related]
32. Toking, Vaping, and Eating for Health or Fun: Marijuana Use Patterns in Adults, U.S., 2014. Schauer GL; King BA; Bunnell RE; Promoff G; McAfee TA Am J Prev Med; 2016 Jan; 50(1):1-8. PubMed ID: 26277652 [TBL] [Abstract][Full Text] [Related]
33. Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity. Wall MB; Pope R; Freeman TP; Kowalczyk OS; Demetriou L; Mokrysz C; Hindocha C; Lawn W; Bloomfield MA; Freeman AM; Feilding A; Nutt D; Curran HV J Psychopharmacol; 2019 Jul; 33(7):822-830. PubMed ID: 31013455 [TBL] [Abstract][Full Text] [Related]
34. A within-person comparison of the subjective effects of higher vs. lower-potency cannabis. Okey SA; Meier MH Drug Alcohol Depend; 2020 Nov; 216():108225. PubMed ID: 32858319 [TBL] [Abstract][Full Text] [Related]
35. A randomised controlled trial of vaporised Δ Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105 [TBL] [Abstract][Full Text] [Related]
38. Do Cannabis Users Reduce Their THC Dosages When Using More Potent Cannabis Products? A Review. Leung J; Stjepanović D; Dawson D; Hall WD Front Psychiatry; 2021; 12():630602. PubMed ID: 33679486 [No Abstract] [Full Text] [Related]
39. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Niesink RJ; Rigter S; Koeter MW; Brunt TM Addiction; 2015 Dec; 110(12):1941-50. PubMed ID: 26234170 [TBL] [Abstract][Full Text] [Related]
40. A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History. Berl V; Hurd YL; Lipshutz BH; Roggen M; Mathur EJ; Evans M Cannabis Cannabinoid Res; 2022 Dec; 7(6):777-789. PubMed ID: 35787693 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]